ĵð´Ù ¸Æ¶ô¸Á¸·¿°¿¡ ÇÕº´µÈ ¸Æ¶ô¸·½Å»ýÇ÷°ü¿¡¼ À¯¸®Ã¼°³» º£¹Ù½ÃÁÖ¸¿ ÁÖÀÔ¼ú Ä¡·á
Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization Secondary to Candida Chorioretinitis
´ëÇѾȰúÇÐȸÁö 2014³â 55±Ç 7È£ p.1106 ~ p.1110
ÀÌ»óÇù(Lee Sang-Hyup) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ÇѾç´ëÇб³º´¿ø ¾È°úÇб³½Ç
ÀÌÁ¤¿í(Lee Jung-Wook) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ÇѾç´ëÇб³º´¿ø ¾È°úÇб³½Ç
½Å¿ë¿î(Shin Yong-Un) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ÇѾç´ëÇб³º´¿ø ¾È°úÇб³½Ç
À̺´·Î(Lee Byung-Ro) - ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ÇѾç´ëÇб³º´¿ø ¾È°úÇб³½Ç
Abstract
Purpose: To report a case of choroidal neovascularization (CNV) secondary to candida chorioretinitis initially treated with an intravitreal bevacizumab injection.
Case summary: A 50-year-old female presented at our clinic with decreased vision and metamorphopsia in her left eye of 5 days duration. She received an anti-fungal treatment 2 months prior due to the presence of endogenous candida choroiditis in both eyes. Fluorescein angiography and optical coherence tomography (OCT) revealed juxtafoveal CNV in her left eye. Three monthly intravitreal injections of bevacizumab were administered as the initial loading dosage. Her visual symptoms improved and CNV regression was observed on OCT. No recurrence or complications were observed during the 6 month follow-up.
Conclusions: Based on the present study results we suggest that intravitreal bevacizumab injection can be used to effectively treat CNV and improve visual symptoms during the treatment of juxtafoveal CNV associated with candida choroiditis.
Å°¿öµå
Bevacizumab, Candida, Choroidal neovascularization, Choroiditis, Intravitreal injection
KMID :
0360220140550071106
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)